• All
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z

• A
• Abrams, Joshua
  Critical Path Institute
• (S-016) Verification of an algorithm for detection of pronation-supination movements in Parkinson’s disease.
  Joshua Abrams
  Favorite
• Abulfathi, Ahmed
  Certara USA Inc
• (M-003) Characterizing the pharmacokinetics of MAM01, an extended half-life monoclonal antibody for the prevention of malaria using a population approach
  Ahmed Abulfathi
  Favorite
• (M-004) Optimal Sampling Workflows with NMsim and NONMEM
  Ahmed Abulfathi
  Favorite
• Aghaee, Mahya
  University of Florida
• (M-085) An innovative framework to find potential immunotherapy targets using QSP modeling and RNA-seq data
  Mahya Aghaee
  Favorite
• Ahadieh, Sima
  Pfizer
• (S-046) Assessment of Weight Loss by Amylin Receptor Agonists Alone and In Combination with GLP-1 Receptor Agonists: A Model-Based Meta-Analysis
  Sima Ahadieh
  Favorite
• Ahamadi, Malidi
  Sanofi
• (M-069) Population Pharmacokinetic Analysis of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease
  Malidi Ahamadi
  Favorite
• Ahmadi Daryakenari, Nazanin
  Biomedical Engineering, Brown University
• (S-081) Leveraging Kolmogorov–Arnold Networks to Discover Time-Dependent Drug Efficacy Function
  Nazanin Ahmadi Daryakenari
  Favorite
• Ahn, Jae Eun
  Pfizer
• (S-046) Assessment of Weight Loss by Amylin Receptor Agonists Alone and In Combination with GLP-1 Receptor Agonists: A Model-Based Meta-Analysis
  Jae Eun Ahn
  Favorite
• Alaybeyoglu, Begum
  Novartis
• (S-106) Clinical PK characterization of EGT710, a novel coronavirus Mpro inhibitor, and simulation of target attainment rates for efficacious dose prediction
  Begum Alaybeyoglu
  Favorite
• Alexander, Gregory
  Merck
• (T-057) A Model Based Meta Analysis of Ulcerative Colitis for Clinical Remission
  Gregory Alexander
  Favorite
• Alidoost, Mohammadali
  Pfizer
• (M-078) Combining Mechanistic Modeling and Deep Learning for Predicting Survival Probabilities in Oncology
  Mohammadali Alidoost
  Favorite
• Anbari Meybodi, Samira
  Genmab US, Inc.
• (S-094) Development of a Quantitative Systems Pharmacology (QSP) Model of the Complement System Capturing Crosstalk Between the Classical and Alternative Pathways
  Samira Anbari Meybodi
  Favorite
• Anderson, Clifton
  Simulations Plus
• (M-014) Multiple myeloma QSP model enables evaluation of iberdomide dosing schedules post-ASCT in NDMM patients for the EXCALIBER Maintenance study
  Clifton Anderson
  Favorite
• (M-015) Hybrid MBMA-QSP Model Predicts T Cell Engager Plus Cereblon E3 Ligase Modulatory Drugs Combination Outcomes As A Function Of Prior Therapies In Relapsed/refractory Multiple Myeloma
  Clifton Anderson
  Favorite
• Anderson, Hannah
  Moffitt Cancer Center
• (T-089) A Framework for Developing a Virtual Murine Cohort: Applications to Adoptive Cell Therapy in Bladder Cancer
  Hannah Anderson
  Favorite
• Anderson, Wes
  Critical Path Institute
• (M-080) Harnessing Machine Learning and Real-World Data: Comparative Analysis of Cross-Sectional and Longitudinal Clustering in Patient Trajectories from Electronic Health Records
  Wes Anderson
  Favorite
• Attarwala, Husain
  Aera Therapeutics
• (S-107) Semi-Mechanistic Model for LNP-mediated In-vivo CAR T-Cell Engineering and B-Cell Depletion in Primates
  Husain Attarwala
  Favorite